The shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day’s high of Rs 2,286 following a landmark $2 billion licensing deal with U.S. pharma giant AbbVie for its cancer drug, ISB …
Glenmark Pharmaceuticals shares rally up to 20%, mutual funds lead the charge over retail investors
view original post